Table 7 Sites of cancer recurrence in lung adenocarcinoma patients with different initial afatinib dosages
Recurrence | All patients | Afatinib 30 mg daily | Afatinib 40 mg daily | P value |
|---|---|---|---|---|
Number of recurrent sites -n (%) | Â | Â | Â | 0.3222 |
 No recurrence | 89 (50%) | 47 (46%) | 42 (55%) |  |
 1 site | 67 (37%) | 43 (42%) | 24 (31%) |  |
  ≥ 2 sites | 23 (13%) | 12 (12%) | 11 (14%) |  |
Details of recurrent sites | ||||
 Central nervous system | 34 (19%) | 18 (18%) | 16 (21%) | 0.5969 |
 Lung | 38 (21%) | 23 (23%) | 15 (19%) | 0.6192 |
 Pleura or pleural effusion | 16 (9%) | 11 (11%) | 5 (6%) | 0.3191 |
 Bone | 16 (9%) | 13 (13%) | 3 (4%) | 0.0399 |
 Liver | 8 (4%) | 5 (5%) | 3 (4%) | 0.7471 |
 Other sites | 7 (4%) | 2 (2%) | 5 (6%) | 0.1214 |